A study from a large metropolitan registry of psoriatic arthritis (PsA) patients showed several racial and/or ethnic groups are underrepresented and demonstrate differences in disease activity.

RheumNow recently highlighted a publication that reported about a third of physicians in academia intend to leave. To our colleagues in non-academic situations, this may seem incredibly high. I think an important contributor to the intention to leave academics is that something that used to be a benefit has now become a challenge: namely, teaching.

 For many aspiring mothers with autoimmune disease, pregnancy can be daunting and full of unknowns. In some cases, those suffering from specific autoimmune conditions have chosen to forego pregnancy altogether due to concerns about their disease treatments and adverse pregnancy outcomes.

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week we discuss hipsters undergoing hip replacement, pregnancy outcomes in RA and the future of academic clinicians.

Somewhere between 24 and 50 million Americans have an autoimmune disease, a condition in which the immune system attacks our own tissues. As many as 4 out of 5 of those people are women. Rheumatoid arthritis, multiple sclerosis and scleroderma are examples of autoimmune disorders marked by lopsided female-to-male ratios. The ratio for lupus is 9 to 1; for Sjogren’s syndrome, it’s 19 to 1.

US commercial insurance claim analysis of laboratory screening and monitoring practices in chronic inflammatory skin disease (CISD) patients shows that < 60% received the recommended pretreatment testing when starting systemic immunomodulatory treatment.

A cross-sectional survey of academic physicians shows that approximately one-third intend to leave their institutions in the next two years. Burnout, lack of professional fulfillment, and other personal and organizational factors were associated with intention to leave. A survey was adminstered to 37 511 attending-level medical specialists at 15 academic medical institutions between May 2022 to March 2023.

A new study has found that the brain system enabling us to inhibit our own pain changes with age, and that gender-based differences in those changes may lead females to be more sensitive to moderate pain than males as older adults.

Ultrasound subclinical synovitis is found in a third of individuals at risk of rheumatoid arthritis (RA) patients; in half of these, subclinical synovitis resolves with a favorable outcome.

Low back pain is a major cause of disability around the globe, with more than 570 million people affected. In the United States alone, health care spending on low back pain was $134.5 billion between 1996 and 2016, and costs are increasing.

Knee osteoarthritis (OA) pain was worse with a pro-inflammatory diet, an observational study suggested. Scores on a proprietary "Dietary Inflammatory Index" (DII) were significantly associated with standard knee pain scores among patients over nearly 11 years of follow-up (β=0.21, 95% CI 0.004-0.43), according to Feng Pan, MBBS, MMed, PhD, of the University of Tasmania in Hobart, Australia, and colleagues.

The trouble with rheumatology may be the words we live by. Welcome to the eulogy for rheumatology 'dead words'. We're here today to celebrate the loss of rheumatology past. These are dead words in rheumatology, words fortified unfortunately by history and habit. The lexicon of rheumatology is unique, it's challenging and it's mostly incomprehensible to those who don't know...but those are the cornerstones of the greatest of medical

A prospective cohort study suggests the presence of antidrug antibodies may be associated with bDMARDs nonresponse in rheumatoid arthritis (RA). Should we be monitoring ADAbs (especially in nonresponders)?

A prospective study of the BioSTAR registry estimates the prevalence of cardiovascular disease in rheumatoid arthritis (RA) to be 4.6%.

The RECOVERY trial focused on pediatric MIS-C patients treated with immunomodulators and anti-cytokine therapy demonstrated the benefits of first-line therapy with intravenous methylprednisolone or second-line tocilizumab in children refractory to initial treatment. Neither IV immunoglobulin nor anakinra benefitted the duration of hospital stay.